{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:52:19Z","timestamp":1740135139501,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T00:00:00Z","timestamp":1649462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T00:00:00Z","timestamp":1649462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Invasive fungal diseases (IFD) remain a major complication of allogeneic hematopoietic stem cell transplantation (alloHSCT) and are associated with high mortality rates in patients receiving alloHSCT. Antifungal prophylaxis is increasingly being used in the management of IFDs in patients receiving alloHSCT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A post-hoc analysis of the cross-sectional observational AFHEM study was carried out to describe the use of antifungal drugs in real-life clinical practice in alloHSCT recipients hospitalized in French hematological units.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 147 alloHSCT recipients were enrolled; most were adults (<jats:italic>n<\/jats:italic>\u2009=\u2009135; 92%) and had received alloHSCT\u2009&lt;\u20096 months prior to enrollment (<jats:italic>n<\/jats:italic>\u2009=\u2009123; 84%). Overall, 119 (81%) patients received a systemic antifungal therapy; of these, 95 (80%) patients received antifungal prophylaxis. Rates of patients receiving systemic antifungal treatment were similar irrespective of transplant time, neutropenic, and graft-versus-host disease status. Among patients on systemic antifungal treatment, 83 (70%) received an azole, 22 (18%) received an echinocandin, and 16 (13%) received a polyene.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This work provides evidence of the antifungal strategies used in alloHSCT recipients hospitalized in French hematological units. Unlike earlier studies, the AFHEM study showed that prophylaxis appears to be the leading antifungal strategy used in alloHSCT recipients in France.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07216-6","type":"journal-article","created":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T08:02:40Z","timestamp":1649491360000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Systemic antifungal strategies in allogeneic hematopoietic stem cell recipients hospitalized in french hematology units: a post-hoc analysis of the cross-sectional observational AFHEM study\ufeff"],"prefix":"10.1186","volume":"22","author":[{"given":"Mauricette","family":"Michallet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"el Cheikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raoul","family":"Herbrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Caillot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Gangneux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,9]]},"reference":[{"key":"7216_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1439-0507.2010.01961.x","volume":"55","author":"A Mikolajewska","year":"2012","unstructured":"Mikolajewska A, Schwartz S, Ruhnke M. Antifungal treatment strategies in patients with haematological diseases or cancer: from prophylaxis to empirical, pre-emptive and targeted therapy. Mycoses. 2012;55:2\u201316.","journal-title":"Mycoses"},{"key":"7216_CR2","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1586\/14787210.4.3.457","volume":"4","author":"L Strasfeld","year":"2006","unstructured":"Strasfeld L, Weinstock DM. Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents. Expert Rev Anti Infect Ther. 2006;4:457\u201368.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"7216_CR3","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.2174\/138161208785061391","volume":"14","author":"GI Parameswaran","year":"2008","unstructured":"Parameswaran GI, Segal BH, Almyroudis NG. Antifungal agents in hematopoietic stem cell transplantation. Curr Pharm Des. 2008;14:2011\u201321.","journal-title":"Curr Pharm Des"},{"key":"7216_CR4","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1592\/phco.29.11.1306","volume":"29","author":"D McCoy","year":"2009","unstructured":"McCoy D, Depestel DD, Carver PL. Primary antifungal prophylaxis in adult hematopoietic stem cell transplant recipients: current therapeutic concepts. Pharmacotherapy. 2009;29:1306\u201325.","journal-title":"Pharmacotherapy"},{"key":"7216_CR5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/bmt.2010.256","volume":"46","author":"DP Kontoyiannis","year":"2011","unstructured":"Kontoyiannis DP. Antifungal prophylaxis in hematopoietic stem cell transplant recipients: the unfinished tale of imperfect success. Bone Marrow Transplant. 2011;46:165\u201373.","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl 1","key":"7216_CR6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1080\/13693780400019990","volume":"43","author":"EJ Bow","year":"2005","unstructured":"Bow EJ. Long-term antifungal prophylaxis in high-risk hematopoietic stem cell transplant recipients. Med Mycol. 2005;43(Suppl 1):277\u201387.","journal-title":"Med Mycol"},{"key":"7216_CR7","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1182\/blood-2003-08-2644","volume":"103","author":"KA Marr","year":"2004","unstructured":"Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004;103:1527\u201333.","journal-title":"Blood"},{"key":"7216_CR8","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1182\/blood-2002-05-1356","volume":"101","author":"OA Cornely","year":"2003","unstructured":"Cornely OA, Ullmann AJ, Karthaus M. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood. 2003;101:3365\u201372.","journal-title":"Blood"},{"key":"7216_CR9","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1046\/j.1365-2141.2002.03259.x","volume":"116","author":"R Martino","year":"2002","unstructured":"Martino R, Subira M, Rovira M, et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol. 2002;116:475\u201382.","journal-title":"Br J Haematol"},{"key":"7216_CR10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s40121-018-0203-4","volume":"7","author":"JP Gangneux","year":"2018","unstructured":"Gangneux JP, El Cheikh J, Herbrecht R, et al. Systemic antifungal prophylaxis in patients hospitalized in hematology units in France: the AFHEM cross-sectional observational study. Infect Dis Ther. 2018;7:309\u201325.","journal-title":"Infect Dis Ther"},{"key":"7216_CR11","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/bmt.2013.87","volume":"48","author":"J El-Cheikh","year":"2013","unstructured":"El-Cheikh J, Venton G, Crocchiolo R, et al. Efficacy and safety of micafungin for prophylaxis of invasive fungal infections in patients undergoing haplo-identical hematopoietic SCT. Bone Marrow Transplant. 2013;48:1472\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"7216_CR12","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.diagmicrobio.2019.01.011","volume":"94","author":"J El Cheikh","year":"2019","unstructured":"El Cheikh J, Ceballos P, Dalle JH, et al. Micafungin prophylaxis in routine medical practice in adult and pediatric patients with hematological malignancy: a prospective, observational study in France. Diagn Microbiol Infect Dis. 2019;94:268\u201373.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"12","key":"7216_CR13","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"B De Pauw","year":"2008","unstructured":"De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813\u201321.","journal-title":"Clin Infect Dis"},{"key":"7216_CR14","doi-asserted-by":"crossref","unstructured":"Maertens JA, Girmenia C, Br\u00fcggemann RJ, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother. 2018;73:3221-30.","DOI":"10.1093\/jac\/dky286"},{"key":"7216_CR15","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.bbmt.2013.05.018","volume":"19","author":"AK Omer","year":"2013","unstructured":"Omer AK, Ziakas PD, Anagnostou T, et al. Risk factors for invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a single center experience. Biol Blood Marrow Transplant. 2013;19:1190\u20136.","journal-title":"Biol Blood Marrow Transplant"},{"key":"7216_CR16","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12879-015-0855-6","volume":"15","author":"EJ Bow","year":"2015","unstructured":"Bow EJ, Vanness DJ, Slavin M, et al. Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients. BMC Infect Dis. 2015;15:128.","journal-title":"BMC Infect Dis"},{"key":"7216_CR17","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.clinthera.2013.11.010","volume":"36","author":"PD Ziakas","year":"2014","unstructured":"Ziakas PD, Kourbeti IS, Mylonakis E. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis. Clin Ther. 2014;36:292-306.e1.","journal-title":"Clin Ther"},{"key":"7216_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00277-013-1867-1","volume":"93","author":"S Mousset","year":"2014","unstructured":"Mousset S, Buchheidt D, Heinz W, et al. Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2014;93:13\u201332.","journal-title":"Ann Hematol"},{"key":"7216_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/hon.2031","volume":"31","author":"C Girmenia","year":"2013","unstructured":"Girmenia C, Aversa F, Busca A, et al. A hematology consensus agreement on antifungal strategies for neutropenic patients with hematological malignancies and stem cell transplant recipients. Gruppo Italiano Malattie Ematologiche dell\u2019Adulto, Gruppo Italiano Trapianto di Midollo Osseo, Associazione Italiana Ematologia ed Oncologia Pediatrica, Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer and Sorveglianza Epidemiologica delle Infezioni Fungine nelle Emopatie Maligne. Hematol Oncol. 2013;31:117\u201326.","journal-title":"Hematol Oncol"},{"issue":"Suppl 7","key":"7216_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/1469-0691.12041","volume":"18","author":"AJ Ullmann","year":"2012","unstructured":"Ullmann AJ, Akova M, Herbrecht R, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect. 2012;18(Suppl 7):53\u201367.","journal-title":"Clin Microbiol Infect"},{"key":"7216_CR21","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/bmt.2010.175","volume":"46","author":"J Maertens","year":"2011","unstructured":"Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3\u20132009 update. Bone Marrow Transplant. 2011;46:709\u201318.","journal-title":"Bone Marrow Transplant"},{"key":"7216_CR22","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1586\/eri.10.141","volume":"8","author":"NG Almyroudis","year":"2010","unstructured":"Almyroudis NG, Segal BH. Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients. Expert Rev Anti Infect Ther. 2010;8:1451\u201366.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"7216_CR23","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3324\/haematol.2016.152900","volume":"102","author":"F Tissot","year":"2017","unstructured":"Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102:433\u201344.","journal-title":"Haematologica"},{"key":"7216_CR24","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1053\/bbmt.2002.v8.pm12374456","volume":"8","author":"C Junghanss","year":"2002","unstructured":"Junghanss C, Marr KA, Carter RA, et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant. 2002;8:512\u201320.","journal-title":"Biol Blood Marrow Transplant"},{"key":"7216_CR25","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1182\/blood-2003-02-0456","volume":"102","author":"T Fukuda","year":"2003","unstructured":"Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood. 2003;102:827\u201333.","journal-title":"Blood"},{"key":"7216_CR26","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.bbmt.2007.06.013","volume":"13","author":"AC Labb\u00e9","year":"2007","unstructured":"Labb\u00e9 AC, Su SH, Laverdi\u00e8re M, et al. High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation. Biol Blood Marrow Transplant. 2007;13:1192\u2013200.","journal-title":"Biol Blood Marrow Transplant"},{"key":"7216_CR27","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/QCO.0b013e32832db9f3","volume":"22","author":"R Ben-Ami","year":"2009","unstructured":"Ben-Ami R, Lewis RE, Kontoyiannis DP. Invasive mould infections in the setting of hematopoietic cell transplantation: current trends and new challenges. Curr Opin Infect Dis. 2009;22:376\u201384.","journal-title":"Curr Opin Infect Dis"},{"key":"7216_CR28","doi-asserted-by":"publisher","first-page":"5471","DOI":"10.1200\/JCO.2007.12.3851","volume":"25","author":"E Robenshtok","year":"2007","unstructured":"Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol. 2007;25:5471\u201389.","journal-title":"J Clin Oncol"},{"key":"7216_CR29","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1086\/525258","volume":"46","author":"TJ Walsh","year":"2008","unstructured":"Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327\u201360.","journal-title":"Clin Infect Dis"},{"key":"7216_CR30","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","volume":"15","author":"M Tomblyn","year":"2009","unstructured":"Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15:1143\u2013238.","journal-title":"Biol Blood Marrow Transplant"},{"key":"7216_CR31","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3324\/haematol.11665","volume":"94","author":"OA Cornely","year":"2009","unstructured":"Cornely OA, B\u00f6hme A, Buchheidt D, et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica. 2009;94:113\u201322.","journal-title":"Haematologica"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07216-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07216-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07216-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T23:04:32Z","timestamp":1650582272000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07216-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,9]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7216"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07216-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2022,4,9]]},"assertion":[{"value":"5 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the original publication an author's family and given name has been incorrectly tagged. The article has been updated to include it","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and with Good Epidemiological Practices. Approvals from national review boards (Comit\u00e9 Consultatif sur le Traitement de l\u2019Information en mati\u00e8re de Recherche dans le domaine de la Sant\u00e9 and Commission Nationale de l\u2019Informatique et des Libert\u00e9s) were obtained. Patients hospitalized in participating units were required to provide written informed consent prior to inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Mauricette Michallet has been a consultant to Astellas, MSD, and Pfizer. Raoul Herbrecht has been a consultant and speaker to Pfizer and Gilead, respectively. Ibrahim Yakoub-Agha has been a consultant to Astellas Pharma and MSD. Jean El Cheikh declares no conflict of interest. Denis Caillot has been a consultant to Astellas Pharma and MSD. Jean-Pierre Gangneux has been a consultant to Astellas Pharma, Gilead, Merck, and Pfizer.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conmpeting interests"}}],"article-number":"352"}}